Filing Flows › 20/20 Biolabs (AIDX) › Who owns the stock
Who owns 20/20 Biolabs (AIDX) stock
13 funds reported 20/20 Biolabs (AIDX) shares in their latest 13F filings, worth $248K in all. The largest holder is Cresset Asset Management, LLC ($132K). Last quarter 11 funds added to their stakes and 5 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Cresset Asset Management, LLC | 240,122 | $132K | decrease | 2026-06-30 |
| Vanguard Fiduciary Trust | 52,087 | $29K | new | 2026-06-30 |
| Geode Capital Management, LLC | 49,141 | $27K | new | 2026-06-30 |
| Atlantic Union Bankshares | 35,099 | $19K | new | 2026-06-30 |
| Vanguard Capital Management LLC | 24,530 | $13K | new | 2026-06-30 |
| Citadel Advisors LLC | 23,205 | $13K | increase | 2026-06-30 |
| Bank of America | 13,024 | $7K | new | 2026-06-30 |
| Susquehanna International Group, LLP | 10,014 | $6K | new | 2026-06-30 |
| McDonald Partners LLC | 2,800 | $2K | new | 2026-06-30 |
| Signaturefd, LLC | 767 | $422 | new | 2026-06-30 |
| Morgan Stanley | 283 | $156 | new | 2026-06-30 |
| Allworth Financial LP | 172 | $95 | increase | 2026-06-30 |
| UBS Group AG | 3 | $2 | decrease | 2026-06-30 |
20/20 Biolabs' latest quarter
20/20 Biolabs, Q2 2026: revenue $731K (+36% year over year), operating margin -170.3%, net loss $1.5M, operating cash flow −$605K. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most AIDX stock?
By the latest 13F filings: Cresset Asset Management, LLC ($132K); Vanguard Fiduciary Trust ($29K); Geode Capital Management, LLC ($27K); Atlantic Union Bankshares ($19K); Vanguard Capital Management LLC ($13K).
What is the short interest in AIDX?
11,270 shares were sold short at the 2026-10-15 settlement, -75.05% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.